Monday, March 16, 2026

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Aligns With Largest Creditor of C.M., Advancing Planned Acquisition of Israeli Defense Manufacturing Platform; @VWAVInc

AI Defense Stock VisionWave Holdings  (Nasdaq: $VWAV) Aligns With Largest Creditor of C.M., Advancing Planned Acquisition of Israeli Defense Manufacturing Platform; @VWAVInc

Agreement removes structural obstacle and with the goal of strengthening the path toward VisionWave’s proposed 51% acquisition of C.M. Composite Materials

 




 


Investorideas.com, a  top 100 rated investment site for retail Investors following AI and defense stocks, reports on breaking news for VisionWave Holdings, Inc (Nasdaq: VWAV), focused on advanced sensing, autonomy, and AI-driven systems for defense and security applications.

AI News Summary

VisionWave announced an agreement with C.M.'s largest creditor, removing a key structural obstacle to its planned acquisition of a 51% controlling stake in the Israeli aerospace/defense composites manufacturer.The deal aligns settlement obligations, ensures creditor compliance won't breach VisionWave's financing agreements, and includes VisionWave's commitment to provide at least $5 million in funding for C.M.'s working capital and expansion (including potential international moves like India partnerships).C.M., based in Modi’in with 20+ years of experience, 130+ specialists, and real revenue from precision composites for aerospace/defense, is seen as a strategic manufacturing asset for VisionWave's AI-driven defense growth.Interim CEO Doug Davis called it "an important step," noting C.M.'s proven track record could become foundational to VisionWave's portfolio.The acquisition remains subject to customary conditions and approvals (per recent Form 8-K). This clears a hurdle in the ongoing process, with related updates like C.M.'s operational continuity in Israel and exploratory India JV talks.

VisionWave Holdings, Inc (Nasdaq: VWAVtoday announced that it has reached an agreement with the largest creditor of C.M. Composite Materials Ltd. (“C.M.”), a step the Company believes strengthens the path toward completing its previously announced agreement to acquire a 51% controlling interest in the Israeli aerospace and defense manufacturing company.

The agreement seeks to align VisionWave, C.M., and its principal creditor regarding existing settlement obligations and clarifies the framework under which C.M. will continue to satisfy those obligations. VisionWave believes the alignment removes a potential structural obstacle that could otherwise have delayed or prevented completion of the transaction.

Paid News Dissemination on behalf of VWAV  

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/03161-visionwave-vwav-israeli-defense-manufacturer-acquisition.asp

The agreement was disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission and confirms that compliance with C.M.’s creditor settlement obligations will not constitute a breach of VisionWave’s previously disclosed investment and financing agreements related to the transaction. 

The agreement also includes VisionWave’s commitment to provide at least $5 million in funding to support C.M.’s working capital and strategic expansion initiatives. 

Established Aerospace and Defense Manufacturing Platform

C.M., headquartered in Modi’in, Israel, is an advanced composite manufacturing company serving the aerospace and defense sectors. The company operates an integrated engineering and production campus employing more than 130 engineers and manufacturing specialists and has over 20 years of operational experience producing precision composite structures and components used in aerospace and defense systems.

VisionWave believes the company represents a strategic manufacturing platform capable of supporting its broader defense-sector growth strategy.

International Growth Opportunities

VisionWave previously announced that C.M. and VisionWave are evaluating potential international expansion initiatives, including opportunities related to industrial and defense manufacturing partnerships in India, where government policy supports the expansion of domestic defense manufacturing capacity.

While such initiatives remain exploratory, VisionWave believes C.M.’s engineering capabilities and manufacturing expertise could position the company to participate in future global defense supply chains.

Management Commentary

“This agreement represents an important step toward completing the planned transaction. C.M. is an established defense manufacturing company with real revenue, experienced engineering teams, and more than two decades of operational history supporting complex aerospace and defense programs. We believe it has the potential to become a foundational manufacturing asset within VisionWave’s defense portfolio.” Said Doug Davis, Interim Chief Executive Officer of VisionWave.

The proposed acquisition remains subject to the satisfaction of conditions under the previously disclosed investment agreements and other customary closing requirements. Additional details regarding the agreement are available in VisionWave’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a dual-market autonomous systems platform company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and sea.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding VisionWave’s proposed acquisition of C.M. Composite Materials Ltd., anticipated strategic benefits, potential international expansion opportunities, and the Company’s strategic initiatives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," and similar expressions, or by statements that events or trends "may," "will," or "could" occur. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to, the ability to satisfy closing conditions for the proposed transaction, including receipt of required regulatory approvals and satisfaction of other customary closing conditions; the availability of financing on acceptable terms; geopolitical risks associated with operations in Israel and potential expansion into other international markets; risks related to the establishment and operation of facilities outside Israel; integration risks following the acquisition; changes in market conditions affecting the aerospace and defense sectors; risks associated with C.M.’s ongoing creditor obligations and compliance therewith; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

VWAV - Investor Contact: investors@vwav.inc

Website: https://www.vwav.inc


 

VisionWave Holdings is a Featured Defense stock on Investorideas.com

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory: https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy,

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Friday, March 13, 2026

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) on the Move – Morning High of $2.09

 

 


 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) on the Move – Morning High of $2.09

 

 


 

 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors issues a trading and news alert for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

The stock is building on yesterday’s gains, currently trading at $1.96, up 0.23, gaining over 13%. Aethlon has a morning high of $2.09 as of this report.

 

Paid News Dissemination of behalf of AEMD

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03131-aethlon-aemd-stock-on-the-move.asp

 

Aethlon Medical, Inc. (Nasdaq: AEMD) announced yesterday  that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Full news

https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all


Get more 
biotech and medical tech news, articles, podcasts and stock directories

 





Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 

Thursday, March 12, 2026

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on News

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on News

 

 


 

 


(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

The stock gained today on news ,currently trading at 1.7300+0.0794 (+4.81%), with a day’s high of $1.94 on volume of over 859,000 shares as of this report.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

Paid News Dissemination of behalf of AEMD

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03122-aethlon-aemd-maxim-strategic-opportunities.asp

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

About Maxim Group LLC

Founded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan providing a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit www.maximgrp.com.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Full news

https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all


Get more 
biotech and medical tech news, articles, podcasts and stock directories

  






Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 


Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Engages Maxim Group LLC to Evaluate Strategic Opportunities

 

 


 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Engages Maxim Group LLC to Evaluate Strategic Opportunities

 

 


 

 

 (Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Aethlon Medical, Inc. (Nasdaq: AEMDtoday announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

About Maxim Group LLC

Founded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan providing a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit www.maximgrp.com.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the Company’s engagement of Maxim Group LLC, the exploration or identification of potential strategic merger and acquisition alternatives, the possibility, timing or structure of any transaction, and the potential benefits of any such transaction. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. There can be no assurance that the Company’s engagement of a financial advisor will result in the identification or consummation of any transaction. The Company may determine to suspend or terminate the exploration of strategic alternatives at any time, and no timetable has been set for completion of this process. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include, without limitation: the Company’s ability to identify suitable transaction partners; the risk that any discussions with third parties do not result in a definitive agreement; the risk that a transaction, if agreed upon, is not consummated; potential disruption to the Company’s business as a result of the announcement or pendency of a strategic review process; the diversion of management’s time and attention; the Company’s ability to maintain compliance with Nasdaq listing standards; the Company’s ability to raise additional capital; and other risks and uncertainties described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances or disclose developments.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any securities that may be offered in connection with a potential transaction would be offered only pursuant to an effective registration statement or in reliance upon an applicable exemption from registration requirements.

 

Company Contacts:

Jim Frakes

Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

 

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all


Get more 
biotech and medical tech news, articles, podcasts and stock directories

 

 

 

 



Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp